Find all the latest news from Frontier Science Scotland below

choose a category:

HERA

HERA

The HERA trial influenced changes in the standard of care for those with HER2-positive breast cancer. Find out more about the study design and our involvement >>

read more
OlympiA results in the subset of patients from Japan

OlympiA results in the subset of patients from Japan

The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.

read more
EPoS

EPoS

The EPoS (European Polyp Surveillance) study is a group of related randomised controlled clinical trials which aim to address the optimum colonoscopy surveillance interval for patients who have had premalignant polyps identified and removed from the large bowel, in...

read more
NordICC

NordICC

Colorectal cancer (CRC) is major burden in western countries which develops over a long time-interval from precursor lesions which exist in the colon. Colonoscopy can detect and remove the precursor lesions and may therefore be an effective intervention for the...

read more
FINESSE

FINESSE

Frontier Science has worked in partnership with the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and in collaboration with Institut de Recherches Internationales SERVIER on the FINESSE trial. The trial was an open, 3-cohort, phase II...

read more
ALEXANDRA

ALEXANDRA

ALEXANDRA is a clinical trial partnership between Roche, the Breast International Group (BIG), Alliance Foundation Trials (AFT), Institut Jules Bordet (IJB) and Frontier Science. This is a phase 3, multicentre, randomised, open-label study comparing atezolizumab...

read more
TOMORROW

TOMORROW

Frontier Science collaborated with Janssen Actelion on the TOMORROW trial. The study assessed the efficacy, safety and pharmacokinetics of macitentan (Opsumit®) versus standard of care in children with pulmonary arterial hypertension (PAH). Frontier Science (Scotland)...

read more

Let's work together

Simply fill in this quick form and we’ll be back in touch within the next two working days. Alternatively, you can call us during usual business hours or send us an email.

3 + 13 =